Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor most people, Wegovy side effects that were present during treatment clear within a few days to two weeks of stopping. Nausea, loose stools and stomach discomfort tend to resolve first; appetite returning to pre-treatment levels usually follows within one to four weeks as semaglutide clears the body. These are prescription-only medicines; a prescriber should always guide any decision to stop or pause treatment, because the timeline varies between individuals and the reason for stopping matters clinically.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine it's been five or six days since your final injection. You might still feel a little queasy after meals, or notice your appetite hasn't quite returned to normal yet. That's expected. Semaglutide has an elimination half-life of roughly one week, meaning the active drug concentration in your bloodstream is halving about every seven days. Most of the clinical effect (including the appetite suppression that made eating less feel manageable) fades gradually rather than all at once.
The gastrointestinal side effects that bother people most during treatment (nausea, an unsettled stomach, loose stools, belching) are closely tied to the drug's effect on gastric emptying. As semaglutide clears, gastric motility returns toward its baseline rate. For the majority of people, nausea and other GI symptoms resolve within a few days to two weeks of stopping, though the exact timeline varies from person to person. A useful checking habit: keep a brief note on your phone of what you ate and how you felt each morning for the first ten days after stopping, a pattern of steady improvement is reassuring; anything worsening rather than settling is worth reporting to your prescriber or GP.
The NHS medicines page for semaglutide gives a clear overview of the side-effect profile during and after treatment, and is a reliable first reference if you want to cross-check what you're experiencing against what's documented.
Stopping Wegovy doesn't just mean side effects go away. The mechanisms that made it effective also unwind. The appetite suppression that helped you eat less was an active pharmacological effect; without it, hunger signals typically return to pre-treatment levels over the weeks following the last dose. Clinical evidence from the STEP trial programme showed that a significant proportion of weight lost during treatment was regained in the months after stopping, particularly without continued lifestyle support.
This is worth knowing not to alarm you, but because it shapes how the conversation with your prescriber should go before you stop. The broader picture of Wegovy side effects after stopping includes both the resolution of GI symptoms and these longer-term physiological shifts. For some people, stopping is planned and managed; for others, a supply issue or a change in circumstances forces a pause. Either way, the body's response follows a broadly predictable trajectory, even if the exact timing differs from person to person.
If you're mid-treatment and wondering whether what you're experiencing is typical, the duration of Wegovy side effects during treatment is a separate but related question worth reading alongside this one.
Most symptoms after stopping Wegovy are mild and resolve without intervention. But there are signals that warrant prompt medical assessment, and stopping the medicine doesn't change that calculus.
Seek urgent medical help for: severe, persistent abdominal pain (especially pain that spreads to your back) with or without vomiting. This is the symptom pattern associated with pancreatitis, which the MHRA highlighted in a Drug Safety Update published in January 2026 as a known but infrequent serious risk with GLP-1 medicines. Gallbladder problems, including gallstones, can also occur. Symptoms like severe right-sided abdominal or shoulder pain, fever, and jaundice need same-day assessment.
Signs of a serious allergic reaction (facial swelling, difficulty breathing, a rapid or severe rash) need a 999 call immediately. These reactions are rare but are not dose-dependent; they can occur at any point during or after treatment. If something feels wrong and you're unsure whether it's related to stopping Wegovy or something unconnected, a call to 111 is always appropriate. The full Wegovy side-effect guide covers these warning signs in more detail for anyone who wants the complete picture.
If you stopped recently and are experiencing nausea or other symptoms you didn't report during treatment, you can still file a report through the Yellow Card scheme, post-treatment reports are valuable and do contribute to ongoing safety monitoring.
Stopping Wegovy, whether temporary or permanent, is a clinical conversation rather than a solo decision. If you're pausing because of side effects that felt unmanageable, that's important information for a prescriber to know, it may influence the dose at which treatment restarts, or whether a different approach suits you better. If you stopped due to cost or access issues, a clear picture of how private Wegovy access works in the UK might be useful before you decide your next step.
At nume, our GPhC-registered prescribers discuss side-effect history as a standard part of every consultation, including for people restarting treatment after a break. They review each case personally; your previous experience directly informs their assessment. You can read more about our clinical approach on the clinical team page, or explore what treatment options we support if you're weighing up where to go next.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.